These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38927508)

  • 1. COVID-19 Infection in Autosomal Dominant Polycystic Kidney Disease and Chronic Kidney Disease Patients: Progression of Kidney Disease.
    Lai S; Tinti F; Perrotta AM; Salomone L; Cianci R; Izzo P; Izzo S; Izzo L; De Intinis C; Pellicano C; Gigante A
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
    Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease.
    Oberdhan D; Yarlas A; Bjorner JB; Krasa H
    Kidney Med; 2024 Jan; 6(1):100755. PubMed ID: 38192435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical and Mutational Spectrum of 69 Turkish Children with Autosomal Recessive or Autosomal Dominant Polycystic Kidney Disease: A Multicenter Retrospective Cohort Study.
    Tutal O; Gulhan B; Atayar E; Yuksel S; Ozcakar ZB; Soylemezoglu O; Saygili S; Caliskan S; Inozu M; Baskin E; Duzova A; Hayran M; Topaloglu R; Ozaltin F
    Nephron; 2024; 148(5):319-332. PubMed ID: 36657418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
    Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
    Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin system activation: may it increase frequency of obstructive sleep apnea in patients with autosomal dominant polycystic kidney disease?
    Yalin SF; Atahan E; Gundogdu S; Parmaksiz E; Mese M; Trabulus S; Mutlu B; Altiparmak MR
    Sleep Breath; 2023 Aug; 27(4):1359-1363. PubMed ID: 36372815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum uromodulin levels, MR imaging findings, and their relationship with eGFR-based CKD staging in ADPKD patients.
    Cansever HN; Sari F; Cevikol C; Cetinkaya R; Süleymanlar G; Ersoy F
    Int Urol Nephrol; 2021 Jul; 53(7):1383-1389. PubMed ID: 33389516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
    Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease.
    Blanchette CM; Liang C; Lubeck DP; Newsome B; Rossetti S; Gu X; Gutierrez B; Lin ND
    Drugs Context; 2015; 4():212275. PubMed ID: 25922609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease.
    Borrego Utiel FJ; Herrera Contreras I; Merino García E; Camacho Reina MV; Moriana Domínguez C; Ocaña Pérez E
    Int Urol Nephrol; 2022 Apr; 54(4):873-881. PubMed ID: 34279821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method.
    Rodríguez RM; Luis-Lima S; Fernandez JM; Gómez MVP; Toledo BG; Cobo M; Delgado-Mallén P; Escamilla B; Marco CO; Estupiñán S; Perera CC; Mena NN; Martín LD; Reyes SP; González IH; González-Rinne F; González-Delgado A; Ferrer-Moure C; Zulueta BL; Torres A; Rodriguez Pérez JC; Gaspari F; Ortiz A; Porrini E
    J Nephrol; 2022 Nov; 35(8):2109-2118. PubMed ID: 35357684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
    Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
    Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Edwards ME; Chebib FT; Irazabal MV; Ofstie TG; Bungum LA; Metzger AJ; Senum SR; Hogan MC; El-Zoghby ZM; Kline TL; Harris PC; Czerwiec FS; Torres VE
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1153-1161. PubMed ID: 30026287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
    Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.